Coherus Biosciences (CHRS) just unveiled an announcement.
Coherus BioSciences, Inc. has expanded its Board of Directors and appointed Rita A. Karachun, a seasoned financial expert with extensive experience at Merck & Co., Inc., and AT&T Corp., as its newest member. Ms. Karachun, also joining the Audit Committee, will serve as a Class II director until the 2025 annual meeting. With her notable track record, including leading finance and accounting for AT&T’s IPO, she brings valuable expertise to the board. Additionally, she has been granted a stock option and will receive standard compensation and indemnification as per the company’s policies for non-employee directors.
See more data about CHRS stock on TipRanks’ Stock Analysis page.
